High-b-Value Diffusion MR Imaging and Basal Nuclei Apparent Diffusion Coefficient Measurements in Variant and Sporadic Creutzfeldt-Jakob Disease

References

1. 1.↵
   1. Kallenberg K,
   2. Schulz-Schaeffer WJ,
   3. Jastrow U,
   4. et al

   . Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol 2006;27:1459–62

   Abstract/FREE Full TextGoogle Scholar
2. 2.↵
   1. Shiga Y,
   2. Miyazawa K,
   3. Sato S,
   4. et al

   . Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004;63:443–49

   Abstract/FREE Full TextGoogle Scholar
3. 3.↵
   1. Tschampa HJ,
   2. Kallenberg K,
   3. Urbach H,
   4. et al

   . MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 2005;128:2026–33

   Abstract/FREE Full TextGoogle Scholar
4. 4.↵
   1. Murata T,
   2. Shiga Y,
   3. Higano S,
   4. et al

   . Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 2002;23:1164–72

   Abstract/FREE Full TextGoogle Scholar
5. 5.↵
   1. Young GS,
   2. Geschwind MD,
   3. Fischbein NJ,
   4. et al

   . Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005;26:1551–62

   Abstract/FREE Full TextGoogle Scholar
6. 6.↵
   1. Tribl GG,
   2. Strasser G,
   3. Zeitlhofer J,
   4. et al

   . Sequential MRI in a case of Creutzfeldt-Jakob disease. Neuroradiology 2002;44:223–26

   CrossRefPubMedWeb of ScienceGoogle Scholar
7. 7.↵
   1. Tschampa HJ,
   2. Zerr I,
   3. Urbach H

   . Radiological assessment of Creutzfeldt-Jakob disease. Eur Radiol 2007;17:1200–11

   CrossRefPubMedWeb of ScienceGoogle Scholar
8. 8.↵
   1. Macfarlane R,
   2. Wroe S,
   3. Collinge J,
   4. et al

   . Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007;78:664–76

   Abstract/FREE Full TextGoogle Scholar
9. 9.↵
   1. Stejskal EO,
   2. Tanner JE

   . Spin diffusion measurements: spin echoes in the presence of a time dependent field gradient. J Chem Phys 1965;42:288–92

   CrossRefWeb of ScienceGoogle Scholar
10. 10.↵
    1. Tha KK,
    2. Terae S,
    3. Yamamoto T,
    4. et al

    . Early detection of global cerebral anoxia: improved accuracy by high-b-value diffusion-weighted imaging with long echo time. AJNR Am J Neuroradiol 2005;26:1487–97

    Abstract/FREE Full TextGoogle Scholar
11. 11.↵
    1. Kim HJ,
    2. Choi CG,
    3. Lee DH,
    4. et al

    . High-b-value diffusion-weighted MR imaging of hyperacute ischemic stroke at 1.5T. AJNR Am J Neuroradiol 2005;26:208–15

    Abstract/FREE Full TextGoogle Scholar
12. 12.↵
    1. Seo HS,
    2. Chang KH,
    3. Na DG,
    4. et al

    . High b-value diffusion (b = 3000 s/mm²) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm². AJNR Am J Neuroradiol 2008;29:458–63

    Abstract/FREE Full TextGoogle Scholar
13. 13.↵
    1. Yoshiura T,
    2. Mihara F,
    3. Tanaka A,
    4. et al

    . High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease. Neuroimage 2003;20:413–19

    CrossRefPubMedGoogle Scholar
14. 14.↵
    1. DeLano MC,
    2. Cooper TG,
    3. Siebert JE,
    4. et al

    . High-b-value diffusion-weighted MR imaging of adult brain: image contrast and apparent diffusion coefficient map features. AJNR Am J Neuroradiol 2000;21:1830–36

    Abstract/FREE Full TextGoogle Scholar
15. 15.↵
    1. Yoshiura T,
    2. Wu O,
    3. Zaheer A,
    4. et al

    . Highly diffusion-sensitized MRI of brain: dissociation of gray and white matter. Magn Reson Med 2001;45:734–40

    CrossRefPubMedGoogle Scholar
16. 16.↵
    1. Trevitt C,
    2. Collinge J

    . A systematic review of prion therapeutics in experimental models. Brain 2006;129:2241–65

    Abstract/FREE Full TextGoogle Scholar
17. 17.↵
    1. Nicoll A,
    2. Collinge J

    . Preventing pathogenicity by targeting the cellular prion protein. Infect Disord Drug Targets 2009;9:48–57

    CrossRefPubMedGoogle Scholar
18. 18.↵
    1. Collinge J,
    2. Gorham M,
    3. Hudson F,
    4. et al

    . Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334–44

    CrossRefPubMedWeb of ScienceGoogle Scholar
19. 19.↵
    1. Hill AF,
    2. Butterworth RJ,
    3. Joiner S,
    4. et al

    . Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353:183–89

    CrossRefPubMedWeb of ScienceGoogle Scholar
20. 20.↵
    1. Tschampa HJ,
    2. Kallenberg K,
    3. Kretzschmar HA,
    4. et al

    . Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol 2007;28:1114–18

    Abstract/FREE Full TextGoogle Scholar
21. 21.↵
    1. Cambier DM,
    2. Kantarci K,
    3. Worrell GA,
    4. et al

    . Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. Clin Neurophysiol 2003;114:1724–28

    CrossRefPubMedWeb of ScienceGoogle Scholar
22. 22.↵
    1. Fukushima R,
    2. Shiga Y,
    3. Nakamura M,
    4. et al

    . MRI characteristics of sporadic CJD with valine homozygosity at codon 129 of the prion protein gene and PrPSc type 2 in Japan. J Neurol Neurosurg Psychiatry 2004;75:485–87

    Abstract/FREE Full TextGoogle Scholar
23. 23.↵
    1. Hamaguchi T,
    2. Kitamoto T,
    3. Sato T,
    4. et al

    . Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 2005;64:643–48

    Abstract/FREE Full TextGoogle Scholar
24. 24.↵
    1. Hirose K,
    2. Iwasaki Y,
    3. Izumi M,
    4. et al

    . MM2-thalamic-type sporadic Creutzfeldt-Jakob disease with widespread neocortical pathology. Acta Neuropathol (Berl) 2006;112:503–11

    CrossRefPubMedGoogle Scholar
25. 25.↵
    1. Zeidler M,
    2. Sellar RJ,
    3. Collie DA,
    4. et al

    . The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412–18

    CrossRefPubMedWeb of ScienceGoogle Scholar
26. 26.↵
    1. Waldman AD,
    2. Jarman P,
    3. Merry RT

    . Rapid echoplanar diffusion imaging in a case of variant Creutzfeldt-Jakob disease; where speed is of the essence. Neuroradiology 2003;45:528–31

    CrossRefPubMedGoogle Scholar
27. 27.↵
    1. Wroe SJ,
    2. Pal S,
    3. Siddique D,
    4. et al

    . Clinical and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion. Lancet 2006;368:2061–67

    CrossRefPubMedWeb of ScienceGoogle Scholar
28. 28.↵
    1. Lin YR,
    2. Young GS,
    3. Chen NK,
    4. et al

    . Creutzfeldt-Jakob disease involvement of rolandic cortex: a quantitative apparent diffusion coefficient evaluation. AJNR Am J Neuroradiol 2006;27:1755–59

    Abstract/FREE Full TextGoogle Scholar
29. 29.↵
    1. Tschampa HJ,
    2. Murtz P,
    3. Flacke S,
    4. et al

    . Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study. AJNR 2003;24:908–15

    Abstract/FREE Full TextGoogle Scholar
30. 30.↵
    1. Russmann H,
    2. Vingerhoets F,
    3. Miklossy J,
    4. et al

    . Sporadic Creutzfeldt-Jakob disease: a comparison of pathological findings and diffusion weighted imaging. J Neurol 2005;252:338–42

    CrossRefPubMedGoogle Scholar
31. 31.↵
    1. Oppenheim C,
    2. Brandel JP,
    3. Hauw JJ,
    4. et al

    . MRI and the second French case of vCJD. Lancet 2000;356:253–54

    CrossRefPubMedWeb of ScienceGoogle Scholar
32. 32.↵
    1. Murata T,
    2. Shiga Y,
    3. Higano S,
    4. et al

    . Conspicuity and evolution of lesions in Creutzfeldt-Jakob disease at diffusion-weighted imaging. AJNR Am J Neuroradiol 2002;23:1164–72

    Abstract/FREE Full TextGoogle Scholar
33. 33.↵
    1. Mittal S,
    2. Farmer P,
    3. Kalina P,
    4. et al

    . Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:128–34

    CrossRefPubMedWeb of ScienceGoogle Scholar
34. 34.↵
    1. Lim CC,
    2. Tan K,
    3. Verma KK,
    4. et al

    . Combined diffusion-weighted and spectroscopic MR imaging in Creutzfeldt-Jakob disease. Magn Reson Imaging 2004;22:625–29

    CrossRefPubMedWeb of ScienceGoogle Scholar
35. 35.↵
    1. Haik S,
    2. Dormont D,
    3. Faucheux BA,
    4. et al

    . Prion protein deposits match magnetic resonance imaging signal abnormalities in Creutzfeldt-Jakob disease. Ann Neurol 2002;51:797–99

    CrossRefPubMedWeb of ScienceGoogle Scholar
36. 36.↵
    1. Collie DA,
    2. Summers DM,
    3. Sellar RJ,
    4. et al

    . Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol 2003;24:1560–69

    Abstract/FREE Full TextGoogle Scholar
37. 37.↵
    1. Garcia Santos JM,
    2. Ordonez C,
    3. Torres dR S

    . ADC measurements at low and high b values: insight into normal brain structure with clinical DWI. Magn Reson Imaging 2008;26:35–44

    CrossRefPubMedGoogle Scholar
38. 38.↵
    1. Niendorf T,
    2. Dijkhuizen RM,
    3. Norris DG,
    4. et al

    . Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging. Magn Reson Med 1996;36:847–57

    PubMedWeb of ScienceGoogle Scholar
39. 39.↵
    1. Clark CA,
    2. Le Bihan DL

    . Water diffusion compartmentation and anisotropy at high b values in the normal brain. Magn Reson Med 2000;44:852–59

    CrossRefPubMedWeb of ScienceGoogle Scholar